Molecular Partners AG is a Switzerland-based clinical-stage biotech company developing DARPin (Designed Ankyrin Repeat Proteins) a new class of custom-built protein therapeutics based on natural binding proteins that open a new dimension of multi-functionality and multi-target specificity in drug design. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
BörsenkürzelMOLN
Name des UnternehmensMolecular Partners AG
IPO-datumOct 22, 2014
CEODr. Patrick Amstutz, Ph.D.
Anzahl der mitarbeiter159
WertpapierartOrdinary Share
GeschäftsjahresendeOct 22
AddresseWagistrasse 14
StadtSCHLIEREN
BörseSIX Swiss Exchange
LandSwitzerland
Postleitzahl8952
Telefon41447557700
Websitehttps://www.molecularpartners.com/
BörsenkürzelMOLN
IPO-datumOct 22, 2014
CEODr. Patrick Amstutz, Ph.D.
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten